Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

Journal Articles

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Jose Valentín García Gutiérrez, MD PhD, Jerald P. Radich, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD PhD, Tamas Masszi, MD PhD Prof., Andrzej Hellmann, MD PhD, Jesper Stentoft, MD PhD, María Teresa Gomez Casares, MD PhD, Eibhlin Conneally, MB, PhD MRCP, MRCPath, Philipp D le Coutre, MD, Norbert Gattermann, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MD FRCPI, FRCPath, Paola Aimone, MD, Sai Li, MD PhD, Ksenia Titorenko, MS, David M. Ross, MD MBBS, PhD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137388

Published: 2020

Journal Articles

Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-137603

Published: 2020

Journal Articles

Prognosis of Acute Myeloid Leukemia with Myelodysplasia-Related Changes According to the Different Subgroups of the WHO 2016 Classification in Patients Candidates to Intensive Chemotherapy

Claudia Nunez-Torron, MD, Juan Marquet Palomanes, Valentín Garcia-Gutiérrez, MD PhD, Adolfo Saez, Alejandro Luna, MD, Jesus Villarrubia, PhD, Gemma Moreno Jiménez, MD, Javier Lopez Jimenez, MD PhD, Pilar Herrera Puente

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-141683

Published: 2020

Journal Articles

Prognostic Impact of the Latency Time from the Administration of Cytotoxic Therapy to the Development of Therapy-Related Myeloid Neoplasms

Claudia Nunez-Torron, MD, Adolfo Saez, Berta Mercedes Michael Fernández, Irene Garcia-Garcia, Juan Marquet Palomanes, Miguel Piris-Villaespesa, MD, Jesus Villarrubia, PhD, Valentín Garcia-Gutiérrez, MD PhD, Gemma Moreno Jiménez, MD, Javier Lopez Jimenez, MD PhD, Pilar Herrera Puente

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-141907

Published: 2020

Journal Articles

Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial

Jorge E. Cortes, MD, Philipp D le Coutre, MD, Carlo Gambacorti-Passerini, MD, Henrik Hjorth-Hansen, MD, Pia Raanani, MD, Valentín Garcia-Gutiérrez, MD PhD, Vamsi Kota, MD, Simon Purcell, Andrea Viqueira, Eric Leip, Tim H Brümmendorf, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-134912

Published: 2020

Journal Articles

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-138690

Published: 2020

Journal Articles

Prognosis Impact of Positive Minimal Residual Disease By Flow Cytometry Prior to Transplant According to the Cut-Off Threshold in Patients with Acute Myeloid Leukemia

Claudia Nunez-Torron, MD, Fernando Martin Moro, Juan Marquet Palomanes, Miguel Piris-Villaespesa, MD, Ernesto Roldan, Alejandro Luna, MD, Adolfo Saez, Valentín Garcia-Gutiérrez, MD PhD, Lucía Rubio, Maria Eulalia Rodriguez, Anabelle Chinea, MD, Ana Lario, Gemma Moreno Jiménez, MD, Javier Lopez Jimenez, MD PhD, Pilar Herrera Puente

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-139954

Published: 2020

Journal Articles

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Jorge E. Cortes, MD, Jane Apperley, FRCP, FRCPath, MB, Andreas Hochhaus, MD, Michael J. Mauro, MD, Philippe Rousselot, MDPhD, Tomasz Sacha, MDPhD, Moshe Talpaz, MD, Charles Chuah, MD, Jeffrey H. Lipton, MD PhD, Michael W. Deininger, MD PhD, Charles A. Schiffer, MD, Lori J. Maness, MD, James K. McCloskey, MD, Valentín García Gutiérrez, MD PhD, Hugues de Lavallade, MD PhD, Gabriel Etienne, MD PhD, Vickie Lu, PhD, Shouryadeep Srivastava, MBBS, PhD, Gianantonio Rosti, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-135883

Published: 2020

Journal Articles

Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

Tim H Brümmendorf, MD, Jorge E. Cortes, MD, Dragana Milojkovic, Carlo Gambacorti-Passerini, MD, Richard E. Clark, MA, MD MRCP, FRCPath, Philipp D le Coutre, MD, Valentín Garcia-Gutiérrez, MD PhD, Charles Chuah, MD, Vamsi Kota, MD, Jeffrey H. Lipton, MD PhD, Philippe Rousselot, MDPhD, Michael J. Mauro, MD, Andreas Hochhaus, MD, Rafael Hurtado Monroy, MD, Eric Leip, Simon Purcell, Anne Yver, PharmD, Andrea Viqueira, MD, Michael W. Deininger, MD PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-137393

Published: 2020

Journal Articles

Identification of Immunological Parameters Related to Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission

Valentín Garcia-Gutiérrez, MD PhD, Lorena Vigon, Laura Checa, Alejandro Luna, MD, Miguel Piris-Villaespesa, MD, Sara Rodriguez-Mora, Guiomar Bautista, Juan Luis Steegmann, Prof., MD, Vicente Planelles, Jose Alcamí, Maria Rosa López-Huertas, Maria Teresa Coiras

Blood (2019) 134 (Supplement_1): 191.

https://doi.org/10.1182/blood-2019-130017

Published: 2019

Journal Articles

Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database

Blood (2019) 134 (Supplement_1): 498.

https://doi.org/10.1182/blood-2019-124430

Published: 2019

Journal Articles

Clinical Validation of the Myelofibrosis Transplant Scoring System in an Independent Series of Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Transplantation

Blood (2019) 134 (Supplement_1): 5733.

https://doi.org/10.1182/blood-2019-126036

Published: 2019

Journal Articles

Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 Mg on Treatment Free-Remission Rate in Patients with Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response with Imatinib (PonaZero_study)

Valentin Garcia Gutierrez, MD PhD, Luis Felipe Casado, Rosa Ayala, MD PhD, Fermin Sanchez-Guijo, MD PhD, Juan Carlos Hernandez Boluda, María Teresa Gomez Casares, Blanca Xicoy, MD MSc, Begonya Maestro, PhD, Juan Luis Steegmann, Arturo Garcia de Diego

Blood (2019) 134 (Supplement_1): 5904.

https://doi.org/10.1182/blood-2019-125627

Published: 2019

Journal Articles

Clinical Characteristics and Cardioavscular Events in Patients with Esential Thrombocythemia with <10% Vs. ≥10% JAK2 V617F Allele Burden

Blood (2019) 134 (Supplement_1): 4171.

https://doi.org/10.1182/blood-2019-126980

Published: 2019

Journal Articles

Proposal of a "2-Step-Algorithm" for the Screening of Myeloproliferative Neoplasms in Individuals with Erythrocytosis

Miguel Piris-Villaespesa, MD, Gloria Muñoz-Martin, PhD, Claudia Stock, PhD, Adolfo Saez-Martin, MD, Ricardo Sanchez, PhD MD, Javier Zamora, Francisco Javier del Castillo, Jesus Villarrubia, PhD, Javier Lopez Jimenez, MD PhD, Joaquin Martinez-Lopez, MD PhD, Valentin Garcia Gutierrez, MD PhD

Blood (2019) 134 (Supplement_1): 4187.

https://doi.org/10.1182/blood-2019-127389

Published: 2019

Journal Articles

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified: Discordance between Histology and Flow Cytometry in Bone Marrow Examination at Diagnosis

Fernando Martín Moro, Miguel Piris-Villaespesa, Monica Garcia Cosio, MD, Jesus Villarrubia, PhD, Juan Marquet Palomanes, MD, Ana Lario Arribas, MD, Eulalia Rodríguez Martín, María Calbacho, MD, Irene Garcia-Garcia, Berta Mercedes Michael Fernández, Carla Martínez-Geijo Román, Kyra Velázquez-Kennedy, Alejandro Sanz, Pilar Herrera Puente, Gemma Moreno Jiménez, Jose Valentín García Gutiérrez, MD PhD, Javier Lopez Jimenez, MD PhD

Blood (2018) 132 (Supplement 1): 1718.

https://doi.org/10.1182/blood-2018-99-117041

Published: 2018

Journal Articles

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

Neil P. Shah, MD PhD, Jose Valentín García Gutiérrez, MD PhD, Antonio Jiménez-Velasco, MD, Sarah Larson, MD, Susanne Saussele, MD, Delphine Rea, MD, François-Xavier Mahon, MD PhD, Moshe Yair Levy, MD, María Teresa Gómez-Casares, MD PhD, Fabrizio Pane, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Oumar Sy, PhD, Patricia Martin Regueira, MD, Jeffrey H. Lipton, MD PhD

Blood (2018) 132 (Supplement 1): 4253.

https://doi.org/10.1182/blood-2018-99-116563

Published: 2018

Journal Articles

rs2431697, a Polymorphism of Mir-146a, Is a Precozing Marker of Progression to Secondary Myelofibrosis: New Epigenetic Regulation of Jak/Stat3 Signaling

Blood (2018) 132 (Supplement 1): 3072.

https://doi.org/10.1182/blood-2018-99-119221

Published: 2018

Journal Articles

Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain

Luis Felipe Casado Montero, Valentin Garcia Gutierrez, MD, Pilar Giraldo, MD PhD, Manuel Perez-Encinas, Raquel de Paz, Joaquin Martinez-Lopez, Guiomar Bautista, Santiago Osorio, Maria Jose Requena, Luis Palomera, MD PhD, Maria Jesús Peñarrubia, Carmen Calle, Jose Angel Hernandez-Rivas, Nuria García-Ormeña, Juan Luis Steegmann, MD PhD

Blood (2016) 128 (22): 3074.

https://doi.org/10.1182/blood.V128.22.3074.3074

Published: 2016

NARROW

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

Prognosis of Acute Myeloid Leukemia with Myelodysplasia-Related Changes According to the Different Subgroups of the WHO 2016 Classification in Patients Candidates to Intensive Chemotherapy

Prognostic Impact of the Latency Time from the Administration of Cytotoxic Therapy to the Development of Therapy-Related Myeloid Neoplasms

Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Prognosis Impact of Positive Minimal Residual Disease By Flow Cytometry Prior to Transplant According to the Cut-Off Threshold in Patients with Acute Myeloid Leukemia

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

Identification of Immunological Parameters Related to Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission

Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database

Clinical Validation of the Myelofibrosis Transplant Scoring System in an Independent Series of Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Transplantation

Clinical Characteristics and Cardioavscular Events in Patients with Esential Thrombocythemia with <10% Vs. ≥10% JAK2 V617F Allele Burden

Proposal of a "2-Step-Algorithm" for the Screening of Myeloproliferative Neoplasms in Individuals with Erythrocytosis

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified: Discordance between Histology and Flow Cytometry in Bone Marrow Examination at Diagnosis

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

rs2431697, a Polymorphism of Mir-146a, Is a Precozing Marker of Progression to Secondary Myelofibrosis: New Epigenetic Regulation of Jak/Stat3 Signaling

Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only